Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Prexasertib (Primary) ; Cytarabine; Fludarabine
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 27 Mar 2018 Planned End Date changed from 1 May 2021 to 1 May 2022.
- 05 May 2016 Planned primary completion date changed from 1 Apr 2021 to 1 May 2021.
- 05 May 2016 Status changed from not yet recruiting to recruiting.